RECRUITING

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

Talk to us

Conditions

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Diseaseoxalate synthesisoxalate metabolismMASLD

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Official Title

Non Alcoholic Fatty Liver Disease and Endogenous Oxalate Synthesis

Quick Facts

Study Start:2023-04-26
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06735924

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * age \>18 years
  2. * History of MASLD, with liver fat content \> 5%
  3. * Normal kidney function
  4. * Stable medication for at least 1 month for diabetes mellitus if any
  5. * Willingess to ingest fixed diets and stop dietary supplements for the study and come to UAB for visits
  1. * Age \< 18 years
  2. * Inaccurate 24-hour urine collections
  3. * Liver fat content \<5%
  4. * Liver cirrhosis
  5. * Evidence of other chronic liver disease, viral hepatitis
  6. * history of alcoholism within 2 years of enrollment
  7. * Contra-indication to Magnetic Resonance Imaging
  8. * Chronic kidney disease with estimated Glomerular Filtration rate \< 60 ml/min/1.73m2
  9. * Type 1 Diabetes Mellitus or treatment with insulin
  10. * Uncontrolled diabetes
  11. * Pregnancy, lactation or intention to be
  12. * Uncontrolled hypertension
  13. * Use of weight loss medication, SGLT2 inhibitors, GLP-1 receptor agonists, osteoporosis medication, chronic NSAID
  14. * History of gastric or intestinal surgery or resection that could potentially alter oxalate absorption
  15. * Chronic fat malabsorption
  16. * Use of immunosuppressive medications
  17. * Known immuno-compromised status
  18. * Active malignancy or treatment for malignanacy within the last 12 months

Contacts and Locations

Study Contact

Kyle D Wood, MD
CONTACT
2059968765
kylewood@uabmc.edu
Sonia Fargue, PhD
CONTACT
2059756932
sfargue@uabmc.edu

Principal Investigator

Kyle D Wood, MD
PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35294
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

  • Kyle D Wood, MD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-26
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2023-04-26
Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

  • oxalate synthesis
  • oxalate metabolism
  • MASLD

Additional Relevant MeSH Terms

  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease